Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma
Advanced Science · 2025-10 · 12 (40)
DOI: 10.1002/advs.202417795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 28.07.2025. Verfasst von Xiaohu Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College …. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Copper, Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai Municipality, Innovative Research Team of High-level Local University in Shanghai.
Abstract (Originalsprache)
High copper levels are required for tumor initiation and progression, termed cuproplasia. However, its role and underlying mechanisms in oral squamous cell carcinoma (OSCC) remain poorly understood. It is find that copper and its transporter SLC31A1 accumulate extensively in OSCC. Blocking copper influx through SLC31A1 siRNA or copper chelators significantly represses OSCC both in vitro and in vivo. Single‐cell RNA sequencing and multiplex immunohistochemical staining revealed that copper chelators specifically decrease the stem‐like tumor epithelial cell subpopulation. Further investigation shows that intratumoral copper depletion reduces histone methyltransferase EZH2 expression at the protein level, but not at the mRNA level, as determined through a screen analysis of histone‐modification enzymes. Mechanistically, it is discovered that silencing SLC31A1 and treating with copper chelators increase p62‐mediated EZH2 ubiquitination at the Ub‐K63 site by suppressing copper binding to SMURF2, an E3 ligase of EZH2, leading to its autophagic degradation. Additionally, combining copper chelators with anti‐PD‐1 treatment effectively suppresses tumor growth, and high levels of SLC31A1 are notably associated with non‐response to anti‐PD‐1 treatment. In conclusion, the crucial role of copper in modulating EZH2 protein stability is demonstrated, and a new approach using copper chelators and anti‐PD‐1 therapy for OSCC patients is provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, No. 639, Zhizaoju Rd, S…
- National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai, 200011, China.
- Shanghai Key Laboratory of Stomatology, Shanghai, 200011, China.
- Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, No. 639, Zhizaoju Rd, Shanghai, 200011, China.
- Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, 100070, China.
- Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shan…
ORCID-Profile: Wei Cao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai Municipality
- Innovative Research Team of High-level Local University in Shanghai
- Shanghai "Rising Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents
- Beijing Science and Technology Commission
Zitieren
APA
Lin, X., Chen, W., Li, B., Zhao, Z., Yu, Z., Zhao, X. Y., Zhou, X., Feng, Z., Lin, C., & Cao, W. (2025). Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma. Advanced Science, 12(40). https://doi.org/10.1002/advs.202417795
Vancouver
Lin X, Chen W, Li B, Zhao Z, Yu Z, Zhao XY, et al. Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma. Advanced Science. 2025;12(40). doi:10.1002/advs.202417795
BibTeX
@article{Lin2025,
author = {Lin, Xiaohu and Chen, Wanling and Li, Bo and Zhao, Zhang and Yu, Zhonglin and Zhao, Xu-Yun and Zhou, Xuan and Feng, Zhien and Lin, Chengzhong and Cao, Wei},
title = {Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {40},
doi = {10.1002/advs.202417795}
}
EUVIMED